Abstract:
Background:
Knowledge about the impact of mild-to-moderate atopic dermatitis (AD) on patients’ physical and mental health in the United States (US) is limited.
Objective:
To describe clinical, humanistic, and economic burdens of mild-to-moderate AD in US adults.
Methods:
Data were analyzed from the 2017 National Health and Wellness Survey (NHWS). NHWS respondents with a self-reported physician’s diagnosis of AD or eczema comprised the AD cohort. Self-reported outcomes assessed included the presence of comorbidities, AD-related sleep disruption severity and impact, anxiety, depression severity, quality of life, mental health, and work and activity impairment.
Results:
A total of 4321 respondents in the AD cohort were matched with 4321 respondents in a non-AD control cohort. Comorbidities reported more commonly in the AD versus control cohort included allergies, pain, hypertension, high cholesterol, and food allergies (P < 0.05 for all). Self-reported anxiety, sleep difficulties, and depression were more frequent in the AD versus control cohort (P < 0.0001 for all). Poorer quality of life, worse functional status, and greater impairments to work productivity and daily activity were reported in the AD versus control cohort (P < 0.0001 for all).
Conclusions:
Mild-to-moderate AD negatively impacts physical, mental, and social domains in adults in the US.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
0.03 MB0.00 MB 
